Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
…and 5/12 is fifteen days after the originally planned ship date of 4/27, which for the upcoming publication would be the longest time frame between planned and actual ship dates. Given the fact that actual is usually before the planned ship date, one can’t help but wonder if, and hope that, this is related to NWBO’s long-awaited journal article.
VNDM’s 60000 ask at $1.50 looks good.
Yep, and Judge too.
Unless I'm missing something, I sincerely hope, at the very least, that NWBO discusses DCVax-L TLD (along with a possible DCVax-Direct update) at ASCO/IET, and if TLD is not released prior to the ASM announcement and proxy vote for additional shares, then they probably have more loans lined up. Otherwise, the ASM would have to be postponed until after June.
PM, I’ll have to clear it with the others in casting, but if you’re right, you’ll be given the option to play yourself in Seasons 6 & 7.
kabunushi, okay, let’s compromise, how about Rowan Atkinson?
No, James Woods hands down :)
Odoggy, I'm partial to the MD Anderson Cancer Center in Houston. They provided excellent medical and patient care for my wife who was diagnosed with cervical cancer in 2014. They saved her life. Also, the Jesse James Rotary House, managed by Marriott, is an adjacent property connected to the main medical complex building via an enclosed skybridge with free golf cart shuttles for patients and families if you don't want to walk. The Rotary House also has free shuttles to nearby Rice Village for shopping, restaurants, groceries, etc. That said, I don't know if they are tops in the USA for your loved one's type of cancer. God bless, V.
Pedes, ASCO 2022 is scheduled for June 3-7 in Chicago.
M2P, correct me if I’m wrong, but the goal is that DCVax-L will treat all operable malignant tumors and Direct all inoperable, so the former wouldn’t be a small market.
iwasadiver opined the same awhile back. I think you guys may be on to something.
It’s been posted that Cofer Black (et. al) was sued twice.
pfelg, you were close, but a little more time is needed until the pps reaches $2. As OTLK management has stated, the BLA should be completed by end of 1Q 2022, or any day now, and the corresponding PR should also boost the share price with FDA approval being very possible before the end of the year. Hopefully, that momentum will be maintained headed into 2023.
Cap, this is an interesting angle on the issue:
flipper44, not only smart, but funny too. thank you for your contribution.
RedneckHosier, Yep, Merck is a likely candidate. Someone once told me cheap wines were underrated. It’s true, and thank God for beer. As far as the hard stuff you and PM were talking about, those are also very fine beverages. To the patients. GL.
See you in Hawaii Happy! :)
Interesting insights. Thanks, Doc.
Extremist, I hope a hostile takeover isn't possible with Linda's controlling interest still in hand...
Thanks for the explanation, Doc. Best to you, too.
Thanks for that. Good luck, Ex.
Doc, by write L scripts”, do you mean schedule brain surgeries?
Bullish Jan. 21, 2022 Seeking Alpha article: https://seekingalpha.com/article/4480794-outlook-therapeutics-fda-approval-possible-buyout?mailingid=26453681&messageid=must_reads&serial=26453681.108183&utm_campaign=Must%2BRead%2BJanuary%2B22%2C%2B2022&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads
Excellent point.
Spartex, I’m not saying one way is better than the other. Astute individuals with less risk aversion who’ve done their due diligence profit greatly from weighted investments, hopefully including those that bought NWBO at $5. It’s happened before with other biotech companies. That’s no less of a rational approach than one from a more conservative investor, but it’s definitely a riskier approach.
JMJJ, Just to add, risk is measured across a broad spectrum. For example, one could invest 50%, more than your 10%, of one's portfolio/assets in NWBO, and still prevent from being wiped out. Also, one's total net worth is likely part of the equation.
BO at $40 at some point would be great.
Sir P, your post gave me a shill.
GFTB, Thanks for all the OTLK MB posts. I've got many OTLK shares and down 35% as I bought right before the recent financings last year. I watched the HCW event this morning and liked what the CEO had to say. The trail was designed in coordination with the FDA, BLA submission to FDA this quarter, and a good chance of FDA approval before YE 2022. They also have a pipeline so the stock should go higher than the 12-month price target of $7-8 pps in '23 and beyond. It also sounds like they are going it alone vs. BO with mention of a sales force to launch revenues.
Stonk, not speaking for flipper of course, but just wanted to make sure you were aware that Refrad reported that DI implied it; DI did not state it as fact. Many well-informed posters here believe a rolling BLA has definitely been started and even close to completion.
Yeah, I sold my shares about a month ago, and took a small loss. After some additional dd, I decided it wasn't the right time to buy BLI. I think it's still a good long-term play for those willing to wait.
$7.00, but much higher later due to BO, partnership, or going it alone.
MB, I think you're right, and perhaps a much higher pps much later. I'm glad I'm only 60.
100%. That’s varsity politics.
Imagine if the pps had stayed in the $2 range up until the release of TLD. Nobody would be worried today. But if the trial fails, the pps will drop to pennies in minutes if not seconds. So, the point is that this pps movement prior to TLD is not relevant for most longs. Everything will be fine eventually.
I’m tempted to take up remote viewing :)
Based on 6 Wall Street analysts offering 12 month price targets for Berkeley Lights in the last 3 months. The average price target is $55.75 with a high forecast of $100.00 and a low forecast of $36.00. The average price target represents a 175.04% change from the last price of $20.27. https://www.tipranks.com/stocks/bli/forecast
The 5 analysts offering 12-month price forecasts for Berkeley Lights Inc have a median target of 45.00, with a high estimate of 100.00 and a low estimate of 36.00. The median estimate represents a +122.88% increase from the last price of 20.19.
https://money.cnn.com/quote/forecast/forecast.html?symb=BLI
Plenty of talk of her on the NWBO board. I'm long on NWBO.